Israel Flu Diagnostic and Treatment Market - Strategic Insights and Forecasts (2026-2031)

The Israeli flu diagnostic and treatment market is projected to register a strong CAGR during the forecast period (2026-2031).

Key Highlights

Market Overview

Israel’s Ministry of Health reported 1,869,094 insured people vaccinated against seasonal influenza during the 2025-2026 season. Vaccination coverage remained much higher among people aged 65 and older than among the overall insured population, reinforcing the importance of age and risk status in influenza care. The Ministry also states that children aged 6 months to 5 years require particular attention because they risk complications, while annual vaccination is offered through HMOs and schools.

The purchasing environment favors products that provide clinically useful results within the treatment window. Rapid antigen tests remain relevant where low cost and simple workflows matter, but molecular platforms can command a stronger role when sensitivity, differentiation of influenza A and B, and detection of other respiratory pathogens influence treatment decisions. Roche, Abbott, Cepheid, bioMérieux, QIAGEN, Hologic, QuidelOrtho, and DiaSorin all maintain respiratory testing portfolios that reflect this shift toward faster molecular or multiplex diagnosis.

Key Market Indicators

Market Drivers

Recurring seasonal surveillance and clinical testing. Israel operates a structured influenza surveillance system through the Ministry of Health, while WHO FluNet provides country-level virological data updated weekly from national reference laboratories. Israel’s 2024-2025 surveillance report recorded influenza A and B activity and tracked H1 and H3 subtypes, supporting continued demand for tests that differentiate influenza types and subtypes. The need is strongest when influenza overlaps with RSV and other respiratory infections, since clinicians must distinguish conditions with similar symptoms but different treatment pathways. Multiplex molecular platforms therefore gain value in hospitals, reference laboratories, and selected outpatient settings.

Low vaccination coverage outside high-risk groups. HMO data for 2025-2026 shows that overall influenza vaccination coverage reached 26%, compared with 59% among people aged 65 and older. Coverage among children aged 6-59 months was 14%, while coverage among pregnant women was 34%. These gaps preserve a recurring pool of patients requiring diagnostic assessment and, where clinically indicated, antiviral treatment. The Ministry of Health also provides school vaccination in grades 2-4 and HMO access for the broader population, creating a broad prevention infrastructure but leaving testing demand sensitive to annual uptake.

Faster molecular testing at the point of care. Product development is reducing the time between specimen collection and an actionable respiratory result. Abbott’s ID NOW Influenza A & B 2 reports positive results in as little as five minutes and negative results in 13 minutes, while Roche’s cobas liat Influenza A/B and RSV test provides results in about 20 minutes. These platforms address a specific buyer problem: clinicians need results during the same visit when antiviral treatment or infection-control decisions are time-sensitive. Their commercial value is therefore tied to workflow savings and treatment decisions rather than test volume alone.

Expansion of syndromic respiratory testing. Respiratory symptoms overlap across influenza, RSV, SARS-CoV-2, and bacterial infections. bioMérieux’s BIOFIRE RP2.1 panel can identify up to 23 respiratory targets in about 45 minutes, while QIAGEN’s QIAstat-Dx Respiratory Panel Plus provides multiplex results through a cartridge-based workflow. Such systems support hospitals and laboratories that want one diagnostic workflow to cover several pathogens. In Israel, this can reduce the commercial dependence of suppliers on influenza-only testing and increase the value of platforms that support broader respiratory menus.

Market Restraints and Challenges

Limited test demand when clinical diagnosis is sufficient. Influenza testing does not automatically follow every influenza-like illness. In mild cases, clinicians may manage symptoms without laboratory confirmation, particularly when the result is unlikely to alter treatment. This limits the addressable volume for higher-cost molecular assays. Suppliers therefore face a trade-off between analytical performance and per-test economics, especially in community settings where buyers may prefer simple rapid tests or rely on clinical assessment.

Seasonal concentration creates procurement and inventory pressure. Influenza activity rises during defined seasonal periods, making demand less evenly distributed than for many other infectious-disease tests. Laboratories and HMOs must prepare stocks before the season while avoiding excessive inventory after transmission declines. The Ministry of Health recommends annual vaccination before winter, generally in September or October, which reinforces the seasonal purchasing cycle. Suppliers must manage manufacturing, distribution, and reagent availability around this concentrated demand pattern.

Coverage and reimbursement influence treatment access. Israel’s healthcare system operates through mandatory national health insurance and HMOs, with a defined national healthcare basket and additional HMO services. This structure supports broad access but places pressure on suppliers to demonstrate clinical and economic value within institutional purchasing frameworks. Diagnostic platforms with higher capital costs can face slower adoption when buyers must justify analyzer placement, consumable commitments, service contracts, and testing volumes.

Antiviral use depends on timing and patient risk. Antiviral treatment has greater clinical value when initiated early and is particularly relevant for high-risk patients. Israel maintains specific Ministry of Health guidance for oseltamivir, including provisions for infants under one year, while official pandemic preparedness documents also identify neuraminidase inhibitors as influenza treatment options. Delayed diagnosis, uncertain clinical presentation, and resistance considerations can reduce the commercial benefit of testing or treatment if decisions are not made within the appropriate clinical window.

Major Segment Analysis

Molecular Tests / NAATs

Molecular Tests / NAATs represent a strategically important offering segment because they combine influenza detection with higher analytical sensitivity and, in many platforms, differentiation of multiple respiratory pathogens. Their strongest commercial fit is in hospitals, emergency departments, reference laboratories, and higher-acuity clinical settings where a confirmed result can affect antiviral treatment, isolation, admission, or further testing.

Buyer selection extends beyond assay performance. Laboratories assess turnaround time, instrument footprint, sample workflow, automation, connectivity, reagent stability, and total cost per reportable result. Roche’s cobas platforms, Cepheid’s Xpert systems, Hologic’s Panther Fusion assays, QIAGEN’s QIAstat-Dx systems, and bioMérieux’s BIOFIRE portfolio show different approaches to integrating influenza into broader molecular respiratory testing. The segment should therefore gain commercial relevance where buyers value broader respiratory coverage and rapid turnaround, while cost remains the main constraint in lower-acuity testing.

Competitive Landscape

The Israel market is best characterized as technology-led and procurement-driven, with competition spanning rapid antigen testing, molecular point-of-care systems, laboratory PCR, and syndromic panels. F. Hoffmann-La Roche Ltd combines laboratory and near-patient molecular systems, while Abbott Laboratories competes through rapid and molecular diagnostic platforms. Danaher Corporation, through Cepheid, supplies molecular systems used across laboratory and near-patient settings.

bioMérieux, QIAGEN N.V., Hologic, Inc., QuidelOrtho Corporation, DiaSorin S.p.A., Thermo Fisher Scientific, and GSK plc broaden the competitive field across molecular diagnostics, immunoassays, respiratory panels, and influenza therapeutics.

Competitive differentiation increasingly depends on turnaround time, menu breadth, installed-system compatibility, service capability, and recurring consumable demand. Danaher reported that its diagnostics business sells instruments, consumables, software, and services to hospitals, physician offices, reference laboratories, and other care settings, with recurring revenue representing 89% of 2025 diagnostics sales. QuidelOrtho is also shifting toward molecular point-of-care diagnostics, showing how suppliers are seeking faster testing formats rather than competing only on traditional antigen assays.

Recent Developments

• February 2026: Scinai Biopharma acquired Recipharm Israel’s Yavne manufacturing site, expanding Israeli small-molecule CDMO capabilities; although not influenza-specific, the transaction strengthens local pharmaceutical production infrastructure supporting treatments and diagnostics.

• December 2025: Israel’s Health Ministry purchased approximately 485,000 additional influenza vaccine doses, deploying supplies nationwide; the procurement represented a significant seasonal expansion of available influenza prevention products for Israelis.

• December 2025: Israeli biotech Polyrizon submitted an FDA pre-request for PL-16, an intranasal viral blocker designed to reduce exposure to influenza and cold viruses through a physical nasal barrier.

• August 2025: GSK’s Fluarix received updated Israeli regulatory approval, supporting seasonal influenza immunisation; the Ministry-hosted product document identifies Fluarix as an influenza vaccine and records approval during August.

Regulatory and Policy Environment

Israel’s National Health Insurance Law establishes universal entitlement to the national healthcare basket through the country’s HMO system. The Ministry of Health’s Health Benefits Finder identifies services and medicines covered by the national basket and additional HMO plans, making coverage status an important commercial factor for suppliers. The framework affects how diagnostic and therapeutic products move from regulatory availability to routine purchasing.

Influenza prevention policy also shapes demand. The Ministry of Health recommends annual vaccination and provides influenza vaccination through HMOs, while school programs cover children in grades 2-4 and special-education pupils in grades 1-6. This creates an organized public-health channel that can reduce infection burden while still leaving seasonal diagnostic and treatment requirements.

Surveillance has a second regulatory function. Israel maintains a National Center for Influenza and Respiratory Viruses within its public-health infrastructure, while WHO FluNet integrates national virological data into global influenza surveillance. This supports strain monitoring and helps inform seasonal preparedness. For manufacturers, maintaining appropriate regulatory documentation, local registration, quality systems, and evidence for intended diagnostic use remains essential when entering or expanding within the Israeli market.

Outlook and Strategic Implications

Demand through 2031 will remain tied to seasonal influenza incidence, vaccination uptake, clinical testing behavior, and the ability of providers to justify rapid diagnostic spending. The 2025-2026 vaccination data show a wide gap between older adults and the overall insured population, while pediatric vaccination remains lower than coverage among high-risk older adults. Changes in vaccination behavior can therefore alter the volume and timing of diagnostic and treatment demand from one season to the next.

The commercial opportunity is likely to favor suppliers that combine rapid results with broader respiratory coverage. New molecular products increasingly detect influenza alongside RSV and SARS-CoV-2, allowing buyers to use one platform across several respiratory indications. Roche, Abbott, bioMérieux, QIAGEN, Hologic, Cepheid, and QuidelOrtho are all positioned around different combinations of speed, automation, multiplexing, and point-of-care use.

For suppliers, the main strategic issue is not simply adding influenza assays. Platform placement, reagent continuity, service response, local regulatory support, and integration with laboratory workflows can determine recurring revenue after the initial purchase. For Israeli healthcare buyers, the balance between test cost, turnaround time, clinical utility, and broader respiratory coverage will remain central. Companies that can demonstrate operational value without imposing excessive capital or consumable costs should have a stronger basis for expanding within hospitals, laboratories, HMOs, and community care.

Israel Flu Diagnostic and Treatment Market Scope: